The centre is set to nurture innovation by bringing together local and international companies, government, and medical and academic institutions
Image: The new facility is planned to be constructed at the core center of Wuxi City. Photo: Courtesy of HCmed Innovations.
HCmed Innovations (HCmed), a medical technology company focused on improvement of respiratory health, has announced the opening of Wuxi International Life Science Innovation Park in China.
The facility has been built by the Wuxi municipal government and Wuxi High-tech District and supported by AstraZeneca as a founding partner.
The new life science park is expected to set up an ecosystem where local and international companies, government, and medical and academic institutions will be able to join forces to generate innovative advances in medical research.
HCmed is set to be among the first batch of companies to join Wuxi International Life Science Innovation Park
HCmed is expected to be among the first batch of companies to join Wuxi International Life Science Innovation Park.
The company delivers high-value therapeutic drugs ensuring medications are reached to the lower tract of lungs for controlled treatment for respiratory diseases.
AstraZeneca China vice president Tina Xu said: “AstraZeneca is full with experience in multiple diseases treatments and we look forward to working with the municipal government and Wuxi High-tech District to create a influential ecosystem that can support and accelerate the development of startup company from early research and development through to commercialization, which would benefit patients in China and global.”
The World Health Organization has classified chronic respiratory diseases as one of the four major chronic diseases and in Mainland China, the prevalence of similar respiratory diseases has increased in recent years.
Pulmicort Respules, an inhaled corticosteroid manufactured by AstraZeneca using suspension a formulation that makes it difficult to be nebulized by most mesh nebulizers, with the recurrent issue of mesh clogging.
The innovative delivery technology designed by HCmed features an easy-to-clean mesh nebulizer capable of overcoming the barriers of nebulizing suspensions and generating a promising market in the future.
HCmed said that it was officially invited to set up a research and development centre along with a production facility to tap the market and fulfil the needs of patients by introducing its device.
The new facility is planned to be constructed at the core centre of Wuxi City, facilitating interaction with universities and other research talents for more opportunities in the life science park that counts with AstraZeneca as a founding partner.